Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07358728

OSIA System Bilateral Implantation Efficacy Evaluation in Children With Ear Aplasia

The aim of this study is to compare speech perception in noise with one activated Osia (unilateral) versus two activated Osia (bilateral), in children with high grade microtia/ear atresia fitted with bilateral Osia implants. In order to do these measurements, the enrolled children will get OSIA implants on both sides during a standard surgery procedure. Six months following the implantation, audiologist testing will be done with one implant active compared to both.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

7 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hôpital Necker Enfants Malades

Paris, Île-de-France Region, 75015, France

Location contact

Charlotte CELERIER, MD

CONTACT

[email protected]

01 71 39 67 85 ext. +33

About this study

High grade microtia corresponds to a congenital malformation of the pinna and the external auditory meatus associated with a malformation of the middle ear. Ear atresia a congenital malformation of the external auditory meatus and middle ear, associated to a normal or near norma pinna.

In the case of hearing loss related to high grade microtia or ear atresia, be the type of hearing rehabilitation cannot be achieved with conventional air-conduction hearing aids, due to the absence of an ear canal. Different options are available and reimbursed by French medical insurance system. The Cochlear Osia implant is a semi-implantable bone conduction hearing aids. It is an active, transcutaneous (closed-skin) implant, which has the CE mark and is covered by the Health Insurance Fund for adults.

When deafness is bilateral and unaided, it impacts the development of oral language, daily life, and academic progress. Studies also show that speech perception in noisy environments is impaired. This can be very disabling, especially for young school-aged children. There are also studies showing that sound localization is improved when using two hearing aids.

Although bilateral fitting has benefits, bone conduction hearing aids are not always surgically placed bilaterally in children with ear aplasia and no clinical research has yet been conducted with the OSIA system. The objective of this study is to evaluate the effectiveness of bilateral implantation of the Osia System in children with high grade microtia or ear atresia.

Once the implantation surgery is done, the patient will come back for at least three visits: two adjustment visits, 1 month and 5 months afterwards, and two ENT consultations at 1 month and 6 months. These visits are part of the usual follow-up for children with bone conduction implants. Experimental audiological measurements will be carried out at the 6-month visit.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • To be aged between 7 and 17 years old at the time of enrolment
  • Use spoken French as primary mode of communication
  • Diagnostic of moderate to severe bilateral high grade microtia and/or ear atresia resulting in conductive hearing loss with an ACPTA between 60 and 80 dB and a BCPTA between 0 and 20 dB
  • Fitted with a unilateral or bilateral headband/headband/adhesive bone conduction device for more than 12 months.
  • In case of microtia: after or before ear reconstruction planned using the conventional costal cartilage graft procedure; anatomical conditions allowing implantation of the OSIA outside the area of a future ear reconstruction.
  • To be a medical and audiological candidate for the OSIA system
  • To be affiliated with a health insurance plan or be eligible for it
  • Signed consent from the legal guardian(s)

Exclusion criteria

  • Weight less than 7 kg (CE marking limit)
  • Diagnosed with a severe neurological condition, identified by an MRI and/or a neuropediatric assessment
  • Diagnosed with a severe cognitive impairment, child psychiatric impairment, or developmental delay
  • Diagnosed with a severe cochleovestibular or cochlear nerve malformation
  • Live in a social context that does not allow for long-term follow-up
  • To be part of a family that does not understand spoken French
  • Already equipped with one (or two) bone conduction implant(s)
  • Affiliated with minimum state healthcare (AME)
  • To currently be pregnant or breastfeeding

Treatment and study plan

Audiological tests

Other

FraSIMAT (French Simplified Matrix Test) and ERKI tests will be performed with one activated implant versus both activated 6 months after surgery

Speech, Spatial and Qualities of Hearing Scale

Behavioral

The patients will answer the SSQ (Speech, Spatial and Qualities of Hearing Scale) 6 months after his surgery.

Primary outcomes

  1. Implantation success

    Time frame: 6 months

    Successful bilateral versus unilateral implantation identified as an increase of at least 3 dB RSB (signal-to-noise ratio) with bilateral conditions compared to unilateral condition value.

Secondary outcomes

  1. Prosthetic gain

    Time frame: 5 months

    Prosthetic gain measured by preoperative pure-tone and speech audiometry with the removable device preoperatively and with ipsilateral OSIA:

  2. Prosthetic gain

    Time frame: 6 months

    • Prosthetic gain in pure-tone audiometry (difference in mean air conduction with and without the device)
  3. Prosthetic gain

    Time frame: 6 months

    • Prosthetic gain in speech audiometry (difference in SRT (Speech Reception Threshold) with and without the device)
  4. Security and skin tolerance

    Time frame: 6 months

    Occurrence of adverse events/serious adverse events, particularly skin complications (hematoma, local injection, skin erosion related to magnetization)

  5. Sound localization

    Time frame: 6 months

    ERKI localization test with one activated OSIA versus two activated OSIAs

  6. Hearing quality

    Time frame: 6 months

    Speech and spatial hearing quality scale using the SSQ questionnaire (Speech, Spatial and Qualities of Hearing Scale) scaled between 0 (lowest quality) to 10 points (best quality)

  7. Daily use

    Time frame: 6 months

    Time length use of OSIA using the data logging OSIA system

Study contacts

Contact information is provided by the study sponsor or research team.

Charlotte CELERIER, MD

CONTACT

[email protected]

01 71 39 67 85 ext. +33

Gael PLASTOW

CONTACT

[email protected]

01 44 38 18 57 ext. +33

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • URC-CIC Paris Descartes Necker Cochin

Registry information

Acronym: APLOSIA

Important dates

Study start
2026
Primary completion
2026
Study completion
2029
First posted
Jan 22, 2026
Registry last updated
Feb 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.